Oct 9 (Reuters) - The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals’ (ALNY.O) drug to treat a rare and fatal heart disease, citing insufficient evidence of clinical meaningfulness, the company said on Monday.

ALNY

BBIO

<p>Oct 9 (Reuters) - The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals’drug to treat a rare and fatal heart disease, citing insufficient evidence of clinical meaningfulness, the company said on Monday.</p>

US FDA declines to approve expanded use of Alnylam's heart-disease drug

Stocks